MIMEDX Announces First Quarter 2026 Operating & Financial Results Reports First Quarter Net Sales of $59 Million Revises 2026 Net Sales and Adjusted EBITDA Expectations Management to Host Conference Call Today, April 29, 2026, at 4:30 PM ET MARIETTA, Ga., April 29, 2026 -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), today announced operating and financial results for the first quarter 2026. Joseph H. Capper, MIMEDX Chief Executive Officer, commented, "The first quarter of 2026 was adversely impacted as new Medicare reimbursement policies in the advanced wound care space went into effect at the start of the year and led to significant confusion across the industry in nearly every care setting. Additionally, inconsistent implementation by the Medicare Administrative Contractors ("MACs") created even greater challenges for providers and their patients." Mr. Capper continued, "We generated $59 million in net sales in the first quarter of 2026. Our Surgical business continued to perform well, increasing 13% year over year and our Wound business declined 60% . As a result of disruption in the wound care market, we are lowering full-year 2026 net sales expectations to a range of $260 to $290 million. Furthermore, as announced a few weeks ago, we have taken steps to adjust the Company's cost structure in response to current market conditions. The $40 million in annualized savings we expect to generate from those actions will position us for a return to profitability over the balance of the year. After the market normalizes, we would anticipate generating double-digit top-line growth in 2027. “While some disruption was expected, the challenges we are now seeing in the market, coupled with irrational behavior by some industry participants, has added complexity that could not have been anticipated. To compound matters, the wound care market is adjusting to the new reimbursement rules at an extremely slow pace. We are working closely with our customers to help them adapt to the changes. Importantly, as we exited the quarter, we saw promising signs of volume recovery in Wound Care Centers and Hospitals. On the other side of this transition, we will be competing in a far more attractive space and believe MIMEDX is uniquely positioned to lead the market. Our Surgical franchise continues to post double-digit top-line growth, with 50% growth over the past three years," concluded Mr. Capper. First Quarter 2026 Results Discussion Net Sales MIMEDX reported net sales for the three months ended March 31, 2026 of $59 million, compared to $88 million for the three months ended March 31, 2025, a decrease of 33%. During the quarter, Surgical

product sales increased 13% compared to the prior year period, led by sales of AMNIOFIX® and AMNIOEFFECT® and another quarter of double-digit growth of our particulate portfolio. These results were offset by a year-over-year decrease in Wound sales of 60%. The performance of the Wound business in the quarter was negatively impacted by several Medicare reimbursement changes that went into effect on January 1, most notably a payment cap on allowable reimbursement for skin substitutes on a per square centimeter basis, coupled with lagging marketplace adoption due to uncertainties around these rule changes. These pressures were primarily seen in the private office and associated care settings, which previously received Medicare reimbursement under the ASP +6% methodology. Sales of Wound products to Wound Care Centers and Hospitals, while also pressured due to the changing rules, showed modest signs of improvement as the quarter progressed. Gross Profit and Margin Gross profit for the three months ended March 31, 2026, was $42 million, compared to $72 million the prior year period. Gross margin for the three months ended March 31, 2026 was 71%, compared to 81% in the prior year period. The quarter-over-quarter decline in gross margin was driven primarily by the Medicare reimbursement rules negatively impacting the prices of our Wound products. Unfavorable product mix and other higher costs also contributed to the decline. Operating Expenses Selling, general and administrative ("SG&A") expenses for the three months ended March 31, 2026, were $53 million compared to $60 million for the three months ended March 31, 2025. The decrease in SG&A was driven primarily by a non-recurring reversal of stock-based compensation expense as well as lower commissions on lower sales. Research and development ("R&D") expenses for the three months ended March 31, 2026 and 2025, were $4 million and $3 million, respectively. R&D spend in the quarter reflects the randomized controlled trial for EPIEFFECT®, which recently completed enrollment, the launch of CHORIOFIX™ and ongoing investments in the development of future products in our pipeline. Net Income Net loss for the three months ended March 31, 2026 was $11 million compared to net income of $7 million for the three months ended March 31, 2025. Cash and Cash Equivalents As of March 31, 2026, the Company had $160 million of cash and cash equivalents compared to $166 million as of December 31, 2025. As of March 31, 2026, our cash position, net of debt on our balance sheet, was $142 million. Financial Outlook For 2026, MIMEDX now expects 2026 net sales to be in a range of $260 to $290 million. 2026 Adjusted EBITDA is expected to be approximately breakeven on a full year basis.

Longer-term, the Company continues to expect to achieve annual net sales growth in the low double-digits as a percentage with an adjusted EBITDA margin above 20%. Conference Call and Webcast MIMEDX will host a conference call and webcast to review its first quarter 2026 results on Wednesday, April 29, 2026, beginning at 4:30 p.m., Eastern Time. The call can be accessed using the following information: Webcast: Click here U.S. Investors: 877-407-6184 International Investors: 201-389-0877 Conference ID: 13759618 A replay of the webcast will be available for approximately 30 days on the Company’s website at www.mimedx.com following the conclusion of the event. Important Cautionary Statement This press release includes forward-looking statements, including statements regarding (i) our 2026 and longer term financial goals and expectations for future financial results, including revenue, net sales growth and Adjusted EBITDA margin; and (ii) any changes to underlying demand in the Wound segment, and (iii) the impact of our restructuring and cost reduction initiatives, including expected cost savings, on our future profitability and growth. Additional forward-looking statements may be identified by words such as "believe," "expect," "may," "plan," “goal,” “outlook,” "potential," "will," "preliminary," and similar expressions, and are based on management's current beliefs and expectations. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materially from those set forth in the forward-looking statements. Factors that could cause actual results to differ from expectations include: (i) future sales are uncertain and are affected by competition, access to customers, patient access to healthcare providers, the new reimbursement environment, which introduced tighter coverage parameters, lower reimbursement levels in certain categories, and incremental administrative complexity for providers and many other factors; (ii) the Company may change its plans due to unforeseen or evolving circumstances and market response to the reimbursement rules; (iii) the results of scientific research are uncertain and may have little or no value; (iv) our ability to sell our products in other countries depends on a number of factors including adequate levels of reimbursement, market acceptance of novel therapies, and our ability to build and manage a direct sales force or third party distribution relationship; (v) the effectiveness of amniotic tissue as a therapy for particular indications or conditions is the subject of further scientific and clinical studies; (vi) we may alter the timing and amount of planned expenditures for research and development based on regulatory developments; (vii) Medicare spending; and (viii) changes in the size of the addressable market for our products. The Company describes additional risks and uncertainties in the Risk Factors section of its most recent

annual report and quarterly reports filed with the Securities and Exchange Commission. Any forward- looking statements speak only as of the date of this press release and the Company assumes no obligation to update any forward-looking statement. About MIMEDX MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX is dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit www.mimedx.com. Contact: Matt Notarianni Investor Relations 470.304.7291 mnotarianni@mimedx.com Selected Unaudited Financial Information

MiMedx Group, Inc. Condensed Consolidated Balance Sheets (in thousands) Unaudited March 31, 2026 December 31, 2025 ASSETS Current assets: Cash and cash equivalents $ 159,773 $ 166,121 Accounts receivable, net 46,034 75,707 Inventory 26,228 25,340 Other current assets 8,291 10,303 Total current assets 240,326 277,471 Property and equipment, net 4,756 4,713 Deferred tax asset, net 24,127 19,596 Goodwill 19,441 19,441 Intangible assets, net 13,140 14,158 Other assets 6,886 7,274 Total assets $ 308,676 $ 342,653 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Current portion of long term debt $ 1,500 $ 1,500 Accounts payable 11,464 14,528 Accrued compensation 14,524 31,065 Accrued expenses 11,008 11,383 Other current liabilities 6,054 5,790 Total current liabilities 44,550 64,266 Long term debt, net 16,094 16,467 Other liabilities 5,096 5,372 Total liabilities 65,740 86,105 Total stockholders' equity 242,936 256,548 Total liabilities and stockholders’ equity $ 308,676 $ 342,653

MiMedx Group, Inc. Condensed Consolidated Statements of Operations (in thousands, except share and per share amounts) Unaudited Three Months Ended March 31, 2026 2025 Net sales $ 58,991 $ 88,205 Cost of sales 17,368 16,558 Gross profit 41,623 71,647 Operating expenses: Selling, general and administrative 53,231 59,969 Research and development 4,140 3,328 Amortization of intangible assets 301 99 Operating income (16,049) 8,251 Other expense, net Interest income, net 886 506 Other expense, net (168) (145) (Loss) income before income tax (15,331) 8,612 Income tax provision 4,471 (1,589) Net (loss) income $ (10,860) $ 7,023 Basic net (loss) income per common share $ (0.07) $ 0.05 Diluted net (loss) income per common share $ (0.07) $ 0.05 Weighted average common shares outstanding - basic 148,446,017 147,272,324 Weighted average common shares outstanding - diluted 148,446,017 149,677,452 MiMedx Group, Inc. Condensed Consolidated Statements of Cash Flows (in thousands) Unaudited Three Months Ended March 31, 2026 2025 Net cash flows provided by operating activities 1,879 5,299 Net cash flows used in investing activities (5,642) (406) Net cash flows used in financing activities (2,585) (2,878) Net change in cash $ (6,348) $ 2,015 Reconciliation of Non-GAAP Measures In addition to our GAAP results, we provide certain non-GAAP measures including Adjusted EBITDA and related margins, Free Cash Flow, Adjusted Gross Profit, Adjusted Gross Margin, Adjusted Net Income, and Adjusted Earnings Per Share ("Adjusted EPS"). We believe that the presentation of these measures provides important supplemental information to management and investors regarding our performance. These measures are not a substitute for GAAP measures. Company management uses these non-GAAP

measures as aids in monitoring our ongoing financial performance from quarter-to-quarter and year-to- year on a regular basis and for benchmarking against comparable companies. These non-GAAP financial measures reflect the exclusion of the following items: • Share-based compensation - expense recognized related to awards to employees and our board of directors issued pursuant to our share-based compensation plans. This expense is reflected amongst cost of sales, research and development expense, and selling, general, and administrative expense in the unaudited condensed consolidated statements of operations. • Amortization of acquired intangible assets - reflects amortization expense recognized solely related to assets which were acquired as part of a transaction. These expenses are generally reflected in cost of sales in our unaudited condensed consolidated statements of operations. • Transaction-related expenses – reflects expenses incrementally incurred resulting from the consummation of material strategic transactions or the integration of acquired assets or operations into our core business. • Strategic legal and regulatory expenses - relates to litigation and regulatory expenses deemed strategically important to our operations. Litigation expenses primarily relate to legal fees incurred and relate to suits filed against former employees and their employers for violation of non-compete and non-solicitation agreements and certain patent infringement matters. Regulatory expenses relate to legal fees incurred stemming from action taken against the United States Food & Drug Administration ("FDA") surrounding the designation of one of our products. These expenses are generally reflected in selling, general and administrative expense in our unaudited condensed consolidated statements of operations. • Reorganization expense - expenses incurred toward the realignment of our operating strategy. These expenses relate to severance expenses related to certain executive leaders and other employment actions. These expenses are reflected as a component of selling, general, and administrative expense in the unaudited condensed consolidated statements of operations. • Income Tax Adjustment - for purposes of calculating Adjusted Net Income and Adjusted Earnings Per Share, reflects our expectation of a long-term effective tax rate, which is normalized and balance sheet-agnostic. Actual tax expense will be based on GAAP earnings, and may differ from the expected long-term effective tax rate due to a variety of factors, including the tax treatment of various transactions included in GAAP net income and other reconciling items that are excluded in determining Adjusted Net Income and Adjusted EPS. The actual long-term normalized effective tax rate was 25% for each of the quarters ended March 31, 2026 and 2025.

Adjusted EBITDA and Adjusted EBITDA margin Adjusted EBITDA consists of GAAP net income excluding (i) share-based compensation, (ii) income tax provision, (iii) amortization of intangible assets (iv) strategic legal and regulatory expenses, (v) interest (income) expense, net, (vi) depreciation expense, (vii) reorganization expenses, and (viii) transaction- related expenses. Please refer to the tables at the beginning of this press release for reconciliation to GAAP net income. Three Months Ended March 31, 2026 2025 Net (loss) income $ (10,860) $ 7,023 Non-GAAP Adjustments: Strategic legal and regulatory expenses 4,555 1,645 Amortization of intangible assets 1,101 2,646 Depreciation expense 527 558 Transaction related expenses 176 7 Reorganization expenses (7) — Interest (income) expense, net (886) (506) Share-based compensation (1,697) 4,259 Income tax provision (4,471) 1,589 Adjusted EBITDA $ (11,562) $ 17,221 Adjusted EBITDA margin (19.6) % 19.5 % Adjusted Net Income Adjusted Net Income provides a view of our operating performance, exclusive of certain items which are non-recurring or not reflective of our core operations. Adjusted Net Income is defined as GAAP net income plus (i) amortization of acquired intangible assets, (ii) strategic legal and regulatory expenses, (iii) reorganization expenses, (iv) transaction related expenses, and (v) the long-term effective income tax rate adjustment. A reconciliation of GAAP net income to Adjusted Net Income appears in the table below (in thousands): Three Months Ended March 31, 2026 2025 Net (loss) income $ (10,860) $ 7,023 Strategic legal and regulatory expenses 4,555 1,645 Amortization of acquired intangible assets 799 2,547 Transaction related expenses 176 7 Reorganization expenses (7) — Long-term effective income tax rate adjustment (2,019) (1,614) Adjusted net (loss) income $ (7,356) $ 9,608

A reconciliation of various line items included in our GAAP unaudited condensed consolidated statements of operations to Adjusted Net Income for the three months ended March 31, 2026 and 2025 are presented in the tables below (in thousands): Three Months Ended March 31, 2026 Gross Profit Selling, General & Administrative Expense Research and Development Expense Net Loss Reported GAAP Measure $ 41,623 $ 53,231 $ 4,140 $ (10,860) Amortization of acquired intangible assets 799 — — 799 Strategic legal and regulatory expenses — (4,555) — 4,555 Reorganization expenses — 7 — (7) Transaction related expenses — (145) — 176 Long-term effective income tax rate adjustment — — — (2,019) Non-GAAP Measure $ 42,422 $ 48,538 $ 4,140 $ (7,356) Gross Profit Margin 70.6 % Gross Profit Margin, as adjusted 71.9 % Three months ended March 31, 2025 Gross Profit Selling, General & Administrative Expense Research and Development Expense Net Income Reported GAAP Measure $ 71,647 $ 59,969 $ 3,328 $ 7,023 Amortization of acquired intangible assets 2,547 — — 2,547 Strategic legal and regulatory expenses — (1,645) — 1,645 Transaction related expenses — — 7 Long-term effective income tax rate adjustment — — — (1,614) Non-GAAP Measure $ 74,194 $ 58,324 $ 3,328 $ 9,608 Gross Profit Margin 81.2 % Gross Profit Margin, as adjusted 84.1 % Adjusted Earnings Per Share Adjusted Earnings Per Share is intended to provide a normalized view of earnings per share by removing items that may be irregular, one-time, or non-recurring from net income. This enables us to identify underlying trends in our business that could otherwise be masked by such items. Adjusted Earnings Per Share consists of GAAP diluted net income per common share including adjustments for (i) amortization of acquired intangible assets, (ii) strategic legal and regulatory expenses, (iii) transaction-related expenses, and (iv) the long-term effective income tax rate adjustment. A reconciliation of GAAP diluted earnings per share to Adjusted Earnings Per Share appears in the table below (per diluted share):

Three Months Ended March 31, 2026 2025 GAAP net (loss) income per common share - diluted $ (0.07) $ 0.05 Amortization of acquired intangible assets 0.01 0.02 Strategic legal and regulatory expenses 0.03 0.00 Reorganization expenses 0.00 0.00 Transaction related expenses 0.00 0.00 Long-term effective income tax rate adjustment (0.02) (0.01) Adjusted Earnings Per Share (0.05) 0.06 Weighted average common shares outstanding - adjusted 148,446,017 149,677,452 Free Cash Flow Free Cash Flow is intended to provide a measure of our ability to generate cash in excess of capital investments. It provides management with a view of cash flows which can be used to finance operational and strategic investments. Free Cash Flow is defined as net cash provided by operating activities less capital expenditures, including purchases of equipment. A reconciliation of GAAP net cash flows provided by operating activities to Free Cash Flow appears in the table below (in thousands): Three Months Ended March 31, 2026 2025 Net cash flows provided by operating activities $ 1,879 $ 5,299 Capital expenditures, including purchases of equipment (570) (377) Free Cash Flow $ 1,309 $ 4,922 Other Information Net Sales by Product Category by Quarter Below is a summary of net sales by product category (in thousands): Three Months Ended March 31, 2026 2025 Surgical $ 36,374 $ 32,132 Wound 22,617 56,073 Net sales $ 58,991 $ 88,205

Q1:26 Financial Results Conference Call April 29, 2026

Disclaimer & Cautionary Statements This presentation and our earnings call includes forward-looking statements. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materially from those set forth in the forward-looking statements. Such forward-looking statements include statements regarding: • Growing expansion outside of the U.S.; • Our growth expectations in 2026 and beyond, including our growth in surgery, increased funding in targeted research and expanded product portfolio; • Expected results of research and development, including that our efforts will innovate and diversify our product portfolio; • Placental-derived products and their potential clinical benefits; • EPIEFFECT® and CHORIOFIX randomized controlled trial enrollment; • Expectations regarding the reimbursement environment for the Company’s products, including Medicare Spending; • Expectations regarding HELIOGEN®, AMNIOFIX®, AMNIOEFFECT®, as well as Hydrelix, NovaForm®, and G4Derm® Plus driving Surgical growth; • Our expectations that we will continue to advocate for Medicare spending reform; • Exposure to tariffs and the anticipation that they will not impact the Company’s results; • 2026 full-year revenue range and Adjusted EBITDA margin, our Long-term non-GAAP effective tax rates and top-line growth post reform in Medicare spending; • Our ability to manage Private Office and Wound Care Center/Hospital Outpatient dynamics, including adjusting our strategy to remain competitive; and • The Company’s long-term strategy and goals for value creation, the status of its pipeline products, expectations for future products, and expectations for future growth and profitability Additional forward-looking statements may be identified by words such as "believe," "expect," "may," "plan," "potential," "will," "preliminary," and similar expressions, and are based on management's current beliefs and expectations. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materially from those set forth in the forward-looking statements. Factors that could cause actual results to differ from expectations include: • Future sales are uncertain and are affected by competition, access to customers, patient access to hospitals and healthcare providers, the reimbursement environment and many other factors; • The future market for the Company’s products can depend on regulatory approval of such products, which might not occur at all or when expected, and is based in part on assumptions regarding the number of patients who elect less acute and more acute treatment than the Company’s products, market acceptance of the Company’s products, and adequate reimbursement for such therapies; • The process of obtaining regulatory clearances or approvals to market a biological product or medical device from the FDA or similar regulatory authorities outside of the U.S. is costly and time consuming, and such clearances or approvals may not be granted on a timely basis, or at all, and the ability to obtain the rights to market additional, suitable products depends on negotiations with third parties which may not be forthcoming; and • The Company describes additional risks and uncertainties in the Risk Factors section of its most recent annual report and quarterly reports filed with the Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this presentation and the Company assumes no obligation to update any forward-looking statement. | 2 |

Opening Remarks Joseph H. Capper, Chief Executive Officer | 3 |

Q1:26 Recap – Wound Volatility Overshadows Strong Surgical Performance 1) Adjusted Gross Margin and Adjusted EBITDA and related margins are non-GAAP financial measures. See the Appendix for a reconciliation to the nearest GAAP measure. | 4 | Surgical 13% Growth vs. Q1:25 Adj. Gross Margin1 72% GAAP Net Loss $11MM vs. $7MM Net Income in Q1:25 Net Sales $59MM (33%) vs. Q1:25 Adj. EBITDA1 ($12MM) (20%) margin Net Cash $142MM Full Market Release of RegenKit® Wound Gel Began Selling New Surgical Products

Strategic Priority Focus on Continued Product Innovation & Diversification | 5 | Continuing to innovate and evolve our offering for Wound & Surgical Numerous opportunities and areas for expansion Driving higher growth in Surgical Achieving a more balanced business mix between Wound & Surgical

• Meaningful reduction in Medicare spend, due to new payment rate significantly below prior levels and softer demand as providers and patients navigate the new framework. • Patient volume and larger wounds shifting from mobile and home-based care settings back to HOPD & Wound Care Centers, which benefit from sizable application fee. • Significant opportunity to capture volume across care settings as market disruption stabilizes over the balance of the year. CMS Reform Causing Chaos for Wound Care Patients Thus Far in 2026 | 6 | Payment Rate Changes HOPD & Wound Care Centers Private Office & Associated Care Settings ~$1,800 bundled rate per visit ASP +6% plus ~$150 application fee $127.14/sq. cm. fixed rate plus ~$750 application fee $127.14/sq. cm. fixed rate plus ~$150 application fee 2025 2026 2025 2026 Market Implications YTD Implementation Stalling Utilization Withdrawn Inconsistent Rule Enforcement LCDs = Local Coverage Determinations WISeR = Wasteful and Inappropriate Service Reduction MACs = Medicare Administrative Contractors

The Exciting Momentum in Surgical Continues! | 7 | Strong Continued Uptake Across Surgical Portfolio and Continuing to Bring Additional New Products to Market Recent Distribution Agreement Significantly Diversifies Our 510(k) Cleared Product Offering in Surgical

Supporting Our Customers & Diversifying Our Offering While Remaining Unmatched with Data | 8 | Randomized Controlled Trial Enrollment Nearly Complete Randomized Controlled Trial Underway Soon Growing Collection of Published Scientific Research Continuing to Build Clinical Efficacy & Expand Portfolio with 510(k)’s Plans to submit first two 510(k) applications for placental products in 2026 Scientific Reports Published study evaluated DHACM and LHACM allografts for their ability to regulate fibrotic processes as modeled in a physiologically relevant in vitro system. Published study investigated the influence of MIMEDX DHACM and LHACM products on inflammatory response, which supports the healing cascade and tissue repair

Financial Results Doug Rice, Chief Financial Officer | 9 |

$32MM $36MM Q1:25 Q1:26 $56MM $23MM Q1:25 Q1:26 Q1:26 Net Sales Recap | 10 | Q1:26 Wound Q1:26 Surgical • Impact from Medicare reimbursement reform on Jan. 1, inconsistent behavior from MACs and WISeR rollout negatively impacted Wound in Q1:26 Highlights • AMNIOFIX, AMNIOEFFECT and particulate portfolio continue to see strong double-digit year-over-year growth Highlights $88MM $59MM Q1:25 Q1:26 Q1:26 Net Sales

Q1:26 P&L Summary 1) Adjusted Gross Margin, Adjusted EBITDA, Adjusted Net Income and related margins are non-GAAP financial measures. See the Appendix for a reconciliation to the nearest GAAP measure. | 11 | $7MM $10MM $17MM ($11MM) ($7MM) ($12MM) $72 $47MM $13 $3MM $42 $44MM $9 $4MM Q1:25 Q1:26 S&M Adj. EBITDA1GAAP Net Income R&D 53% 74% 4% 7% 8% (18%) 20% (20%) Adj. Net Income1 11% (11%) Gross Profit & Margin 81% 71% G&A 15% 16% Adj. Gross Margin1 84% 72% • Wound-related headwinds resulted in a net loss and a negative adjusted EBITDA in Q1:26 • Recent cost initiatives position us to reach breakeven for the full year NI & Adj. EBITDA • Q1:25 gross margin negatively impacted by product mix and the revised Wound reimbursement rates • Proportionally higher S&M expense driven by agent-related sales GM & Opex

Strong Balance Sheet Continues to Provide Meaningful Optionality | 12 | Quarterly Net Cash Balance ($ Millions) $86 $88 $100 $124 $148 $142 Q4:24 Q1:25 Q2:25 Q3:25 Q4:25 Q1:26 Share Buyback Established Continue to prioritize growth investments as primary use of capital, but intend to implement a program to repurchase shares as market conditions warrant Up to $100MM Authorized

2026 Outlook – Transition Year as Wound Market Re-Sets *2026 and Long-Term Outlooks provided as of April 29, 2026. Actual results may differ. | 13 | $260-290MM Approximately Breakeven 2026 Net Sales* 2026 Adj. EBITDA* Continue to expect to deliver low double-digit net sales growth and a 20%+ Adjusted EBITDA margin long term

Closing Remarks, Q&A | 14 |

THANK YOU MIMEDX 1775 West Oak Commons Ct. Marietta, GA 30062 888.543.1917 | 770.651.9100 | 15 |

Adjusted EBITDA - QTD | 17 | Amounts (in millions) for the three months ended March 31, 2026 March 31, 2025 GAAP net (loss) income $ (10.9) $ 7.0 Strategic legal and regulatory expenses 4.6 1.6 Amortization of intangible assets 1.1 2.6 Depreciation expense 0.5 0.6 Transaction-related expenses 0.2 — Interest income, net (0.9) (0.5) Stock-based compensation expense (1.7) 4.3 Income tax provision (benefit) expense (4.5) 1.6 Adjusted EBITDA $ (11.6) $ 17.2 Adjusted EBITDA margin (19.7)% 19.6 %

Adjusted Net Income and Adjusted EPS - QTD | 18 | Amounts (in millions) for the three months ended March 31, 2026 March 31, 2025 GAAP net (loss) income $ (10.9) $ 7.0 Strategic legal and regulatory expenses 4.6 1.6 Amortization of acquisition-related intangible assets 0.8 2.5 Transaction-related expenses 0.2 — Long-term expected effective tax rate adjustment (25%) (2.0) (1.6) Adjusted net income $ (7.4) $ 9.6 Weighted average common shares outstanding - adjusted (millions) 148.4 149.7 Adjusted earnings per share $ (0.05) $ 0.06

Adjusted Gross Profit and Adjusted Gross Profit Margin - QTD | 19 | Three Months Ended Amounts (in millions) March 31, 2026 March 31, 2025 GAAP gross profit $ 41.6 $ 71.6 Amortization of acquisition-related intangible assets 0.8 2.5 Adjusted Gross Profit $ 42.4 $ 74.1 Adjusted Gross Profit Margin 71.9 % 84.0 %

Free Cash Flow - QTD | 20 | Three months ended Amounts in millions March 31, 2026 March 31, 2025 Cash flows from operating activities $ 1.9 $ 5.3 Purchases of equipment (0.6) (0.4) Free Cash Flow $ 1.3 $ 4.9

Disclaimer & Cautionary Statements This presentation and our earnings call includes forward-looking statements. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materially from those set forth in the forward-looking statements. Such forward-looking statements include statements regarding: • Growing expansion outside of the U.S.; • Our growth expectations in 2026 and beyond, including our growth in surgery, increased funding in targeted research and expanded product portfolio; • Expected results of research and development, including that our efforts will innovate and diversify our product portfolio; • Placental-derived products and their potential clinical benefits; • EPIEFFECT® and CHORIOFIX randomized controlled trial enrollment; • Expectations regarding the reimbursement environment for the Company’s products, including Medicare Spending; • Expectations regarding HELIOGEN®, AMNIOFIX®, AMNIOEFFECT®, as well as Hydrelix, NovaForm®, and G4Derm® Plus driving Surgical growth; • Our expectations that we will continue to advocate for Medicare spending reform; • Exposure to tariffs and the anticipation that they will not impact the Company’s results; • 2026 full-year revenue range and Adjusted EBITDA margin, our Long-term non-GAAP effective tax rates and top-line growth post reform in Medicare spending; • Our ability to manage Private Office and Wound Care Center/Hospital Outpatient dynamics, including adjusting our strategy to remain competitive; and • The Company’s long-term strategy and goals for value creation, the status of its pipeline products, expectations for future products, and expectations for future growth and profitability Additional forward-looking statements may be identified by words such as "believe," "expect," "may," "plan," "potential," "will," "preliminary," and similar expressions, and are based on management's current beliefs and expectations. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materially from those set forth in the forward-looking statements. Factors that could cause actual results to differ from expectations include: • Future sales are uncertain and are affected by competition, access to customers, patient access to hospitals and healthcare providers, the reimbursement environment and many other factors; • The future market for the Company’s products can depend on regulatory approval of such products, which might not occur at all or when expected, and is based in part on assumptions regarding the number of patients who elect less acute and more acute treatment than the Company’s products, market acceptance of the Company’s products, and adequate reimbursement for such therapies; • The process of obtaining regulatory clearances or approvals to market a biological product or medical device from the FDA or similar regulatory authorities outside of the U.S. is costly and time consuming, and such clearances or approvals may not be granted on a timely basis, or at all, and the ability to obtain the rights to market additional, suitable products depends on negotiations with third parties which may not be forthcoming; and • The Company describes additional risks and uncertainties in the Risk Factors section of its most recent annual report and quarterly reports filed with the Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this presentation and the Company assumes no obligation to update any forward-looking statement. | 2 |

Reconciliation of Non-GAAP Measures | 3 | In addition to our GAAP results, we provide certain non-GAAP measures including Adjusted EBITDA, related margins, Free Cash Flow, Adjusted Gross Profit, Adjusted Gross Margin, Adjusted Net Income and Adjusted EPS. • Adjusted EBITDA consists of GAAP net income excluding: (i) depreciation, (ii) amortization of intangibles, (iii) interest (income) expense, net, (iv) income tax provision, (v) share-based compensation, (vi) investigation, restatement and related expenses, (vii) expenses related to disbanding of the Regenerative Medicine business unit, (viii) strategic legal and regulatory expenses, (ix) transaction- related expenses, (x) impairment of intangible assets, and (xi) reorganization expenses. • Adjusted Net Income provides a view of our operating performance, exclusive of certain items which are non-recurring or not reflective of our core operations. Adjusted Net Income is defined as GAAP net income plus (i) loss on extinguishment of debt, (ii) investigation restatement and related expenses, (iii) impairment of intangible assets, (iv) amortization of acquired intangible assets, (v) transaction related expenses, (vi) strategic legal and regulatory expenses, and (vii) expenses related to disbanding of our Regenerative Medicine business unit, and (viii) the long-term effective income tax rate adjustment.

Investment Rationale | 4 | Addressing large & expanding Surgical markets and continuing a legacy of leadership in Wound Attractive opportunities to expand growth through M&A Key competitive advantages with innovative products, extensive IP, proprietary technologies and expansive sales infrastructure Strong balance sheet and cash flow generation Experienced leadership team driving company strategy

MIMEDX – A Pioneer & Leader Delivering Healing Solutions in Healthcare | 5 | At MIMEDX, our vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. EXPANDING SURGICAL FOOTPRINT as we demonstrate positive clinical and economic outcomes using our Surgical products AN INDUSTRY PIONEER in Advanced Wound Care with a product offering backed by a compendium of scientific and clinical evidence STRONG FINANCIAL DISCIPLINE as focused capital deployment and expense management supports continued growth, profitability & cash flow HELPING HUMANS HEAL

Addressing a Large and Unmet Need for Wound Healing Solutions 1 - Sen CK, et al. Human Wound and Its Burden: Updated 2025 Compendium of Estimates. Adv Wound Care (New Rochelle). 2025; doi: 10.1177/21621918251359554 2 - Tettelbach WH, et al. Cost-effectiveness of dehydrated human amnion/chorion membrane allografts in lower extremity diabetic ulcer treatment. J Wound Care. 2022 Feb 1;31(Sup2):S10-S31. 3 - Serena, T. E., et al. Evaluation of lyophilized human amnion/chorion membrane (LHACM) in the management of nonhealing diabetic foot ulcers: An interim analysis of the CAMPAIGN trial. International Journal of Tissue Repair. 2025. https://doi.org/10.63676/tk3kw419 | 6 | Opportunities to Use Innovative Allografts Driven by Combination of Macro Factors and Increased Physician / Surgeon Awareness INCREASING CLINICAL EVIDENCE FAVORABLE DEMOGRAPHIC TRENDS >10 million People in the US suffering from chronic and hard-to-heal wounds1 1 in 6 Medicare beneficiaries affected by these wounds1 Up to 85% Of amputations are avoidable using a wound care approach that incorporates innovative treatments2 EPIFIX® recipients experienced reductions in major amputations and hospital utilization2 98.5% higher Probability of wound closure compared to standard-of-care in latest literature3 ~$150 billion Global expenditure on wound care1

With Enormous Untapped Potential for MIMEDX Surgical Products | 7 | 0 5,000 10,000 15,000 20,000 25,000 30,000 Plastic & Derm General Surgery Urology Orthopedics OB/GYN ENT Cardiac Neuro Spine Vascular Other 000s Significant opportunity for MIMEDX products to be used across disciplines Annual # of Surgical Procedures in the U.S. - 20241 Ortho 40% General / Vascular 25% GYN / Urology 20% Other (incl. Burn) 10% Plastic / Recon 5% MIMEDX Surgical Product Mix by Subspecialty 1 - Source: Life Science Market Research, U.S. Surgical Procedure Volumes Database, accessed April 2026.https://www.lifesciencemarketresearch.com/procedure- volumes/united-states-surgical-procedure-volumes-database

Forging into Several Subspecialties with Our Surgical Portfolio Opportunities across a range of procedures and subspecialties | 8 |

Surgical Studies Underway Highlight Product Versatility | 9 | Generating Clinical Data in Numerous Surgical Disciplines Incorporating Use of MIMEDX Products AMNIOEFFECT in High-Risk Vascular Published April 2026 Vascular Published May 2025 Journal of Drugs in Dermatology EPIFIX in Mohs (HECON) E-Published March 2026 European Surgical Research AMNIOFIX in Complicated Diverticulitis AMNIOFIX in ACL Repair E-Published December 2025 Journal of Orthopaedic Reports AMNIOFIX in Liver Transplant RCT Enrollment Underway Manuscript in development Enrollment Underway AMNIOFIX in Breast Reduction Two manuscripts drafted AMNIOFIX in Esophageal Reconstruction AMNIOFIX in Endoscopic Spine Lumbar Discectomy

Increased Morbidity & Mortality Increased Hospitalization Costs Increased Reoperation Rate Reduced Quality of Life Extended Length of Stay Increased Readmission Rates The Consequences: Anastomotic leak complications include1: Targeting Applications That Reduce Health & Economic Burdens Compelling Data Supporting Use of MIMEDX Products in Colorectal Anastomosis Procedures 1) Rennie O, Sharma M, Helwa N. Colorectal anastomotic leakage: a narrative review of definitions, grading systems, and consequences of leaks. Front Surg. 2024;11:1371567. Published 2024 May 2. 2) Hammond J, Lim S, Wan Y, Gao X, Patkar A. The burden of gastrointestinal anastomotic leaks: an evaluation of clinical and economic outcomes. J Gastrointest Surg. 2014;18(6):1176-1185. | 10 | The Problem: Anastomotic leaks are a serious postoperative complication of intestinal surgeries, with significant health and economic consequences that burden providers, payors and patients A Solution: Recent studies demonstrate AMNIOFIX recipients experienced significant reductions in leak rates and hospital readmissions Per 1,000 patients, the economic burden associated with anastomotic leaks is approximately $28 million2, representing a multibillion cost to the healthcare system.

Over a Decade and a Half Supporting the Patient Journey in Wound Care MIMEDX Wound products are available throughout the continuum of care… | 11 | Mohs surgery Burn/Trauma DFU VLU Limb Salvage Dehiscence Acute Wounds Chronic Wounds Complex Wounds Private Offices Nursing Facilities Wound Care Clinics Assisted Living Facilities Ambulatory Surgery Centers Hospital Outpatient Hospital Inpatient …and others …and are used on a range of chronic and other hard-to-heal wounds

The Most Comprehensive End-To-End Product Ecosystem Leading the field with science, clinical efficacy and a customer and patient-centric go-to-market mindset | 12 | The most studied portfolio of placental products with a growing compendium of published scientific, clinical and health outcome data Large, national placental donation network and proprietary tissue processing. New product innovations leading to untapped opportunities for growth, including an increasing footprint in the Surgical market. A key partner to healthcare professionals with industry leading support services and customer-focused approach.

The Most Comprehensive End-To-End Product Ecosystem Unmatched peer-reviewed published evidence supporting our product portfolio | 13 | The most studied portfolio of placental products with a growing compendium of published scientific, clinical and health outcome data Broadest commercial payor coverage, GPO relationships and increasing hospital value analysis committee wins result in wide product availability Interim RCT Results Demonstrate Clinical Benefit Associated with Use of EPIEFFECT Compared to Standard of Care Publications in Nature Scientific Reports and the Journal of Inflammation are Recent Examples of Top Tier Peer Reviewed Scientific Research Using MIMEDX Products

The Most Comprehensive End-To-End Product Ecosystem National footprint with labor and delivery centers to obtain placental tissue | 14 | Consent for Donation Obtained Delivery of Healthy Baby via Caesarean Section Donated Placental Tissues Recovered Tissues Transported to MIMEDX National Network of Birthing Center Partners Expectant Mothers Introduced to Donation Program Donor Tissue Tested & Prepared for Manufacturing Large, national placental donation network and proprietary tissue processing.

The Most Comprehensive End-To-End Product Ecosystem Leveraging robust IP portfolio, knowhow and expertise to drive continued innovations for Wound & Surgical markets | 15 | New product innovations leading to untapped opportunities for growth, including an increasing footprint in the Surgical market. Ample Placental Supply and Manufacturing Capabilities to Support Continued Growth and Industry Demand Proprietary Processing Backed by Broad Portfolio of Intellectual Property Shelf-Stable, Packaged Product Available to Ship Robust IP Estate with 200+ Patents Significant Opportunity for Continued Scale

The Most Comprehensive End-To-End Product Ecosystem MIMEDX Connect offers a full suite of practice management tools in a single online portal to help customers simplify workflows, maximize efficiency and increase lifetime value of each customer | 16 | A key partner to healthcare professionals with industry leading support services and customer-focused approach. Order management Insurance verification status Bill pay Features include:

Distribution Agreements Significantly Diversify Wound & Surgical Offering | 17 | In the last year, we have added several adjacent products to our Wound & Surgical portfolio through distribution and co-promote agreements, including:

Growing Surgical Footprint Diversifies & Differentiates Our Business | 18 | Surgical Revenue Drivers • Ongoing clinical efficacy and health outcomes studies demonstrating the benefits of MIMEDX products across a range of surgery types • Inorganic expansion opportunities to broaden our product offering, including G4Derm Plus and Hydrelix 2026 & Beyond $0 $20,000 $40,000 $60,000 $80,000 $100,000 $120,000 $140,000 $160,000 $0 00 s Surgical Performance 2023 2024 2025 LTM @ Q1:26 38% LTM Surgical % of Sales LTM = last twelve months as of March 31, 2026

Wound Results Driven by Market Dynamics; Poised to Capitalize in ‘26 & Beyond | 19 | $0 $50,000 $100,000 $150,000 $200,000 $250,000 $300,000 $0 00 s Wound Performance 2023 2024 2025 LTM @ Q1:26 LTM Wound % of Sales Wound Revenue Drivers • Volume share recapture opportunity driven by Medicare reimbursement reform as market adjusts to updated pricing and policy • Expanding Wound offering (e.g., RegenKit®-Wound Gel) • Continued international growth 2026 & Beyond 62% LTM = last twelve months as of March 31, 2026

Financial Highlights LTM = last twelve months as of March 31, 2026 1) EBITDA, Adjusted EBITDA, related margins and Free Cash Flow are non-GAAP financial measures. See our Earnings Releases for the quarter and year ended March 31, 2026 and December 31, 2025 for reconciliations to the nearest GAAP measure. Quarterly Net Cash Balance $389MM +11% year-over-year $142MM Over 4x 2023 YE cash balance $77MM 20% of net sales LTM Net Sales Net Cash Balance LTM Adj. EBITDA1LTM GAAP Net Income $86MM $88MM $100MM $124MM $148MM $142MM Q4:24 Q1:25 Q2:25 Q3:25 Q4:25 Q1:26 $31MM

• Meaningful reduction in Medicare spend, due to new payment rate significantly below prior levels and softer demand as providers and patients navigate the new framework. • Patient volume and larger wounds shifting from mobile and home-based care settings back to HOPD & Wound Care Centers, which benefit from sizable application fee. • Significant opportunity to capture volume across care settings as market disruption stabilizes over the balance of the year. CMS Reform Causing Chaos for Wound Care Patients Thus Far in 2026 | 21 | Payment Rate Changes HOPD & Wound Care Centers Private Office & Associated Care Settings ~$1,800 bundled rate per visit ASP +6% plus ~$150 application fee $127.14/sq. cm. fixed rate plus ~$750 application fee $127.14/sq. cm. fixed rate plus ~$150 application fee 2025 2026 2025 2026 Market Implications YTD Implementation Stalling Utilization Withdrawn Inconsistent Rule Enforcement

After Slow Start to 2026, Promising Signs of Recovery in Wound | 22 | Higher audit and clawback activity Providers adjusting to prior auth requirements in WISeR states Some manufacturers dumping products at very low prices Some providers have completely shut down Market Dynamics in Early 2026 Early Signs of Market Recovery During Q1, began to see volumes returning to the HOPD & Wound Care Center settings Without limitation of prior bundled reimbursement, larger wounds increasingly being treated in HOPD & Wound Care Center settings While activity still remains slower than in prior years, these positive trends suggest a rebound over the balance of 2026 into 2027 Insurance verification requests represent a leading indicator of a rebound in skin substitute utilization Inconsistent enforcement of new reimbursement rules by MACs

Strategic Priority Focus on Continued Product Innovation & Diversification | 23 | Continuing to innovate and evolve our offering for Surgical & Wound Numerous opportunities and areas for expansion Driving higher growth in Surgical Achieving a more balanced business mix between Wound & Surgical

Experienced, Skillful Leadership Team Executing Strategy Prior Roles Include: Management Team with Track Record of Success in MedTech Joe Capper Chief Executive Officer Doug Rice Chief Financial Officer Butch Hulse Chief Administrative Officer & General Counsel Kim Moller Chief Commercial Officer John Harper, Ph.D. Chief Scientific Officer & SVP, R&D Matt Notarianni Head of IR 24| | Tracy Chastain Chief Human Resources Officer Eric Smith SVP, Marketing & International

Summary | 25 | Addressing large & expanding markets Attractive opportunities to expand growth Key competitive advantages Strong balance sheet and cash flow generation Experienced leadership team

THANK YOU MIMEDX 1775 West Oak Commons Ct. Marietta, GA 30062 888.543.1917 | 770.651.9100 | 26 |

Adjusted EBITDA - QTD | 28 | Amounts (in millions) for the three months ended March 31, 2026 March 31, 2025 GAAP net (loss) income $ (10.9) $ 7.0 Strategic legal and regulatory expenses 4.6 1.6 Amortization of intangible assets 1.1 2.6 Depreciation expense 0.5 0.6 Transaction-related expenses 0.2 — Interest income, net (0.9) (0.5) Stock-based compensation expense (1.7) 4.3 Income tax provision (benefit) expense (4.5) 1.6 Adjusted EBITDA $ (11.6) $ 17.2 Adjusted EBITDA margin (19.7)% 19.6 %

Adjusted Net Income and Adjusted EPS - QTD | 29 | Amounts (in millions) for the three months ended March 31, 2026 March 31, 2025 GAAP net (loss) income $ (10.9) $ 7.0 Strategic legal and regulatory expenses 4.6 1.6 Amortization of acquisition-related intangible assets 0.8 2.5 Transaction-related expenses 0.2 — Long-term expected effective tax rate adjustment (25%) (2.0) (1.6) Adjusted net income $ (7.4) $ 9.6 Weighted average common shares outstanding - adjusted (millions) 148.4 149.7 Adjusted earnings per share $ (0.05) $ 0.06

Adjusted Gross Profit and Adjusted Gross Profit Margin - QTD | 30 | Three Months Ended Amounts (in millions) March 31, 2026 March 31, 2025 GAAP gross profit $ 41.6 $ 71.6 Amortization of acquisition-related intangible assets 0.8 2.5 Adjusted Gross Profit $ 42.4 $ 74.1 Adjusted Gross Profit Margin 71.9 % 84.0 %

Free Cash Flow - QTD | 31 | Three months ended Amounts in millions March 31, 2026 March 31, 2025 Cash flows from operating activities $ 1.9 $ 5.3 Purchases of equipment (0.6) (0.4) Free Cash Flow $ 1.3 $ 4.9